Zhaoyan New Pharmaceutical (06127) was announced. On February 5, 2024, the board of directors reviewed and approved the “About...
Zhitong Finance App News, Zhaoyan New Pharmaceutical (06127) announced that on February 5, 2024, the board of directors reviewed and passed the “Proposal on Cooperation between the Company and Professional Investment Institutions to Participate in the Investment and Establishment of Industrial Funds and Related Transactions”, agreeing that the company signed the “Wuxi Jinyifu New Biomedical Investment Partnership (Limited Partnership) Limited Partnership Agreement” to jointly fund the establishment of Wuxi Jin Yi Fu New Biomedical Venture Capital Partnership (Limited Partnership). The total amount of capital pledged by the fund is RMB 1 billion. The company, as a limited partner, has pledged an investment of RMB 300 million, accounting for 30% of the limited partnership. The investment method is monetary investment.
The company has recently signed “Partnership Agreements” with Wuxi Guolian Industrial Investment Private Equity Fund Management Co., Ltd., Beijing Hongru Heyu Investment Management Co., Ltd., Wuxi Innovation Investment Group Co., Ltd., Jiangsu Yuanli Industrial Investment Co., Ltd., and Xiangtang Heyuan (Beijing) Technology Co., Ltd. The total amount of capital pledged by the fund was RMB 1 billion. The company, as a limited partner, actually pledged an investment of RMB 299 million, accounting for 29.90% of the limited partnership. The investment method was monetary investment.
According to the signed “Partnership Agreement”, a limited partner, Xiangtang Heyuan (Beijing) Technology Co., Ltd. (hereinafter referred to as “Xiangtang Heyuan”) was added to this investment fund project. Meanwhile, as one of the limited partners of the fund, Xiangtang Hassai is an affiliated corporation of the company. Xiangtang Group has pledged an investment of RMB 100 million, accounting for 10% of the limited partnership.